Takeda Pharmaceutical Company Limited SEC filings document its reporting as a foreign private issuer and ADR-listed pharmaceutical company that furnishes Form 6-K current reports and files annual reports on Form 20-F. The filings include English-language earnings reports, financial appendices, press releases and governance notices.
Takeda’s regulatory disclosures cover IFRS consolidated results, outlook commentary, ADR and foreign-issuer reporting status, board and representative-director matters, corporate transformation initiatives, and clinical or regulatory updates for programs such as zasocitinib, rusfertide and oveporexton. The filings also document pipeline-related financial-impact statements, shareholder meeting materials and formal exhibits furnished to the SEC.
Takeda Pharmaceutical Company details its FY2025 executive compensation, linking pay closely to financial, R&D and shareholder return metrics. Short-term incentive payouts were based on corporate KPIs, resulting in a Corporate KPI payout multiple of 72.8%, so FY2025 bonuses are more than 40% lower than FY2024.
Long-term Performance Share Unit awards for FY2023–2025 achieved a payout multiple of 130.9%, driven by strong three-year accumulated Core Revenue and Core Operating Profit and an R&D KPI score of 147.7%. Takeda reports a three-year Total Shareholder Return of 51.0%, ranking 7th of 15 peers, and confirms a CEO succession in June 2026, with Julie Kim slated to succeed Christophe Weber.
Takeda Pharmaceutical Company Limited plans to revise its FY2025 consolidated IFRS earnings report after a jury verdict in the AMITIZA® (lubiprostone) antitrust litigation on May 18, 2026 was determined to be an adjusting subsequent event. The company is still assessing the financial impact.
Because the verdict came after the May 12, 2026 audit report date under the Japanese Companies Act, it will not change the Japanese statutory consolidated or unconsolidated financial statements for the year ended March 31, 2026 included in the shareholder meeting materials. Takeda intends to file a revised Earnings Report with the Tokyo Stock Exchange and update other FY2025 financial materials on its website once the impact is finalized.
The company states that it does not expect its FY2026 financial forecast or Management Guidance to be materially impacted, though it may revise these once the assessment is complete.
Takeda Pharmaceutical Company Limited reports that a U.S. federal jury in Massachusetts returned a verdict against the company in AMITIZA (lubiprostone) antitrust litigation, awarding plaintiffs USD 884,943,990 in single damages. This includes USD 474,897,965 for a wholesaler class and USD 346,837,646 for individual retailers, which are subject to automatic trebling under U.S. antitrust law upon entry of judgment. Damages for an end payor class remain subject to further court proceedings.
Takeda states it will vigorously pursue post-trial motions and an appeal and notes the verdict is not enforceable until judgment is entered. The company is assessing a provision to recognize in its consolidated financial statements for the fiscal year ended March 31, 2026 and plans to revise and re-file its FY2025 earnings and related materials once the amount is determined. Takeda indicates this outcome will not affect FY2025 Core financial results and does not expect a material impact on its FY2026 financial forecast or Management Guidance, other than potential changes to adjusted free cash flow depending on the amount and timing of any payment.
Takeda Pharmaceutical Company Limited has approved the continuation of its stock-based incentive plans for directors and management in Japan in 2026. The Board resolved to keep the Board Incentive Plan Trust (BIP) for directors and the ESOP Trust for management, which grant Performance Share Units and Restricted Stock Units tied to roles and performance. The trust terms, originally ending in August 2026, will be extended to August 2029, covering a plan period through the fiscal year ending March 31, 2029. Takeda plans to add 0.8 billion yen to the BIP Trust to fund future share acquisitions for these incentives within a previously approved 5 billion yen overall cap.
Takeda Pharmaceutical Company Limited reported FY2026 revenue of JPY 4,505.7 billion, down 1.7% year-on-year as generic erosion of ADHD drug VYVANSE weighed on Neuroscience, while Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Vaccines all grew.
IFRS operating profit rose to JPY 408.8 billion, up 19.3%, and net profit attributable to owners jumped to JPY 191.8 billion, up 77.7%. Core Revenue slipped 1.6% to JPY 4,505.7 billion, but Core Operating Profit edged up to JPY 1,172.5 billion and Core EPS increased to JPY 517.
Adjusted Free Cash Flow declined 11.0% to JPY 684.5 billion as higher intangible investments and business payments offset strong operating cash flow. Leverage remained moderate, with an Adjusted Net Debt/Adjusted EBITDA ratio of 2.6x. For FY2027, Takeda forecasts revenue of JPY 4,640.0 billion (+3.0%) but expects Core EPS to decline to JPY 472, and management guidance at constant exchange rates calls for low-single digit percentage decline in Core Revenue, a 5–8% decline in Core Operating Profit and a mid-teens percentage decline in Core EPS.
Takeda Pharmaceutical Co. Ltd. filed an initial Form 3 for executive Jennifer Marie Smoter, who serves as Chief Communications & Government Officer. The filing does not report any insider transactions or holdings; it simply establishes her status as a reporting person for future disclosures.
Takeda Pharmaceutical’s President and CEO Christophe Weber received new equity-based compensation awards. On April 27, 2026 he was granted 165,370 American Depositary Shares and 78,900 Ordinary Shares at no cash cost, described as grant or award acquisitions.
The filing notes these awards stem from restricted stock units granted on July 1, 2023, whose final amounts were set by the Compensation Committee based on performance metrics including core revenue, core operating profit and important R&D milestones. Following these grants, Weber directly holds 418,803 American Depositary Shares and 1,014,200 Ordinary Shares.
He also received 78,978 Tax Obligation Awards, each economically equivalent to one Ordinary Share and settling in cash primarily to cover tax obligations at the then-current Ordinary Share market price. After this grant, he holds 125,345 Tax Obligation Awards, alongside additional RSU positions scheduled to vest between 2026 and 2028.
Furuta Milano reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical director and Chief Financial Officer Furuta Milano received equity-based compensation rather than buying shares on the market. On April 27, 2026, Milano was awarded 7,800 Ordinary Shares at no cost following performance-based RSUs tied to core revenue, core operating profit, and R&D milestones, bringing direct ownership to 57,900 Ordinary Shares.
The filing notes that this total includes 27,300 restricted stock units (RSUs), which are scheduled to vest as Ordinary Shares on June 1, 2026 (16,200 shares), June 1, 2027 (7,100 shares) and June 1, 2028 (4,000 shares). Milano also received 7,814 Tax Obligation Awards, economically equivalent to Ordinary Shares but payable in cash at vest primarily to cover tax obligations, with 16,619 such derivative awards held afterward.
Plump Andrew Stewart reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical Co. Ltd. director and President of R&D Andrew Stewart Plump reported a compensation-related equity award. On April 27, 2026, he was credited with 212,470 American Depositary Shares at $0.00 per share as a grant/award linked to earlier restricted stock units.
The award stems from RSUs originally granted on July 1, 2023, which vest in ADSs based on performance metrics including core revenue, core operating profit, and key R&D milestones. After the award, he directly holds 806,572 ADS and indirectly holds 281,307 ADS through a trust. The filing notes unvested RSUs scheduled to vest on July 1, 2026 (329,478 shares), July 1, 2027 (91,580 shares), and July 1, 2028 (43,374 shares), each representing a contingent right to receive one ADS.
Ricci Gabriele reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical granted Chief Data & Technology Officer Gabriele Ricci 34,994 American Depositary Shares on April 27, 2026 as a compensation-related award. This follows a July 1, 2023 grant of restricted stock units tied to performance metrics such as core revenue, core operating profit and important R&D milestones.
After this award, Ricci holds 159,126 American Depositary Shares, including 80,768 restricted stock units. These RSUs are scheduled to vest in tranches on July 1, 2026, July 1, 2027 and July 1, 2028, reflecting a multi‑year incentive structure rather than an open‑market transaction.